Q2 2025 Recap: Revenue +21%, EPS +23%, dV5 Broad Launch + Smooth CEO Transition — Initiating at Outperform

Results vs. Consensus

Q2 2025 delivered a clean beat-and-raise print across every key metric. Revenue +21% with procedure growth +18% and pro forma operating margin 39% — well above Street expectations. The pro forma gross margin compression (-210bp YoY to 67.9%) is the structural watch-out, driven by dV5 + Ion + da Vinci 5 service costs + tariffs, but the operating leverage offset and FY25 GM guide raise (66-67%) signal management confidence.

YoY View

QoQ View

Revenue Assessment

Revenue +21% YoY with da Vinci procedures +17% and Ion procedures +52% (~35K) demonstrates broad-based platform momentum. US da Vinci +14% (driven by benign general surgery + after-hours strength); OUS da Vinci +23% (India, Korea, distributor markets strongest; Japan/China/UK macro pressure tempered). System placements 395 (+16%) with 180 dV5 — broad US launch driving demand inflection. SP procedures +88% in Korea-led market. Recurring revenue 85% of total = durable franchise. Q1→Q2 sequential growth +8.4% normal seasonality.

Margin Assessment

Pro forma gross margin 67.9% (-210bp YoY) — the compression reflects: (a) higher facility costs including depreciation from new manufacturing capacity (Bulgaria), (b) greater mix of lower-margin Ion + dV5 revenue, (c) higher service costs related to dV5 platform support, (d) ~60bp tariff impact. The FY25 GM guide raise to 66-67% (from 65-66.5%) signals management visibility on tariff mitigation + product cost reduction work. Operating margin 39% expanded YoY despite GM compression — fixed cost leverage absorbing GM pressure. The structural pattern: ISRG accepts GM compression at platform transitions in exchange for accelerated market share + future operating leverage.

EPS Assessment

Pro forma EPS $2.19 (+23%) — beat by $0.18 with composition: operating beat ~$0.13, other income beat ~$0.03, tax rate ~$0.02. The +23% EPS growth on +21% revenue + flat tax rate demonstrates the operating leverage story. Share count reduced via $181M Q2 buyback at $518 avg — modest pace but disciplined. The 39% operating margin is the cleanest signal of the operating model intent at scale.

Segment Performance

da Vinci — $1.8B+ I&A + System Revenue; 17% Procedure Growth

da Vinci procedures grew +17% with US +14% (benign general surgery, after-hours strength) and OUS +23% (broad multi-specialty expansion beyond urology). System placements 395 (+16%) with 180 dV5 — installed base now 689 systems. Trade-ins 83 (vs 21 YoY) demonstrating dV5 upgrade momentum. ASP $1.5M (vs $1.44M) — dV5 mix-up driving pricing power. da Vinci utilization +2% YoY (lower than recent given mix shift to new installations).

Assessment: da Vinci is the durable economic engine. The dV5 transition is in early innings — broad US launch only this quarter, Europe + Japan measured launches starting. Multi-year trade-in cycle as Xi-installed customers upgrade. Procedure growth +17% durable; OUS multi-specialty diversification reduces concentration risk.

Ion — $35K Procedures (+52%); Capital Slowdown

Ion procedures ~35K (+52% YoY) — the highest-growth platform. System placements 54 (vs 74 YoY) — placement slowdown reflects management focus on utilization rather than placement expansion. Installed base ~905 systems. Utilization +8% YoY.

Assessment: Ion is at scale but capital placement pace moderating intentionally. The lung cancer market opportunity is structural (the largest single cancer category); Ion's clinical workflow advantages over conventional bronchoscopy creating durable share gain. The slower placement pace + faster utilization growth is the right strategy.

SP — Single-Port; +88% Procedures, Korea-Led

SP procedures +88% YoY with 112% growth in Korea + strong Europe/Japan early progress. System placements 23 (vs 21 YoY). New 510(k) clearances for vessel sealer curved + transanal local excision. SP utilization +30%.

Assessment: SP is the long-term growth optionality. Korea adoption proves the platform can scale internationally; US measured rollout extends through 2025-2026. The SP stapler launch is the gating mechanism for colorectal + thoracic expansion.

Key Topics & Management Commentary

Overall Management Tone: Confident and continuity-focused. Dave Rosa's CEO debut emphasized strategic continuity + bench depth. Jamie Samath CFO commentary was characteristically detailed on segment dynamics. The transition theme was smooth.

1. CEO Transition — Dave Rosa Takes Over

Gary Guthart transitioned to Executive Chair after 15+ years as CEO; Dave Rosa took over. Rosa and Guthart joined Intuitive within a month of each other in 1996 as engineers on the original da Vinci prototype.

"Since then, we have worked together with many extraordinary colleagues to build a company that is today a global enterprise, employing more than 16,000 people, supporting over 11,000 robotic systems across 74 countries with over 17 million procedures performed." — David Rosa, CEO

Assessment: 30-year founding-team continuity reduces transition risk materially. Rosa was effectively co-architect of the company alongside Guthart.

2. da Vinci 5 Broad US Launch (100K Procedures)

dV5 in broad launch US with 100,000+ procedures performed. Europe + Japan clearances enable measured launches. Trade-ins +4x YoY (83 vs 21).

Assessment: The trade-in inflection is the structural signal — US customers committing to multi-year dV5 ecosystem. Each trade-in event preserves the customer relationship while expanding ARPU through dV5 specific I&A + service.

3. Force Feedback Instrumentation — Clinical Evidence Building

Force feedback technology generating early clinical evidence. Customers publishing data through case insights integration.

Assessment: Force feedback is the most-differentiated dV5 feature. Clinical evidence build is multi-quarter; meaningful at scale.

4. OUS Multi-Specialty Expansion — 23% Procedure Growth

OUS da Vinci procedures +23% — India, Korea, distributor markets strongest. Procedure growth across colorectal, benign general surgery, thoracic, kidney, HPB.

Assessment: OUS multi-specialty diversification is the multi-year structural tailwind. ISRG penetration outside US still ~25% of US level — long runway.

5. Tariff Impact Estimate Reduced

Tariff impact estimate reduced to 100bp +/- 20bp (from prior 120bp). Reflects reduction in US-China bilateral tariffs + Mexico/Canada USMCA exemption.

Assessment: Tariff overhang easing. The Bulgaria manufacturing facility provides geographic flexibility for future trade environment shifts.

6. SP Korea Acceleration + Stapler Measured Rollout

SP +112% growth in Korea; stapler in measured rollout. Vessel sealer curved + transanal local excision clearances expanding US TAM.

Assessment: SP scaling in Korea demonstrates international viability. The stapler launch is the gating mechanism for colorectal + thoracic.

7. Bulgaria Manufacturing Facility Opening

New 187K sq ft Bulgaria manufacturing facility opened in Q2. Focused on mature endoscope products initially with capacity for expansion.

Assessment: Bulgaria provides EU manufacturing footprint for OUS supply continuity + tariff flexibility. Strategic positioning for next decade.

8. Ion Capital Slowdown — Intentional

Ion system placements 54 (vs 74 YoY) — slower placement pace intentional. Focus on utilization growth in existing US installed base.

Assessment: Disciplined approach. Procedure growth +52% with placements -27% = utilization compounding.

9. Medicaid + ACA Policy Uncertainty

Management acknowledged potential impacts from fiscal policy to Medicaid recipients (70-80M Americans covered). ISRG has lower relative penetration in Medicaid; Medicaid demographic younger; clinical/economic value provides relative resilience.

Assessment: ACA + Medicaid uncertainty is the lone policy overhang. Management framework for resilience is credible but unproven.

10. Third-Party Instrument Remanufacturing Threat

Management addressed third-party instrument remanufacturing market entry. Positioning: high-quality, predictable supply chain, safety, reliability vs. remanufactured alternatives.

Assessment: Defensive positioning. Multi-year risk if remanufacturers gain regulatory clearance + customer acceptance.

Guidance & Outlook

Analyst Q&A Highlights

dV5 Trade-In Cycle and Upgrade Cadence

Q: "Trade-ins jumped to 83 from 21. How do you think about the multi-year upgrade cycle for the Xi base, and what's the upgrade economics for ISRG?"
— Larry Biegelsen, Wells Fargo

A: "While there are a number of customers expressing interest in upgrading to da Vinci 5, we expect trade-ins to occur over multiple years as customers assess its clinical and financial benefits."
— Jamie Samath, CFO

Assessment: Multi-year trade-in cycle supports sustained system mix-up + accretive pricing through 2027+.

OUS Capital Constraints

Q: "Japan, China, UK capital pressures are headwinds. When do you expect these to inflect?"
— Robbie Marcus, JPMorgan

A: "Our capital performance outside the U.S. continues to be impacted by ongoing financial and budgetary pressures in Japan, China and Europe... we are encouraged to see a commitment to expanding access to robotic surgery as one of the key elements of the plan. However, we do not expect any positive impact this year from incremental NHS investments in robotics."
— Jamie Samath, CFO

Assessment: OUS macro headwinds are temporary not structural. NHS 10-year plan supportive long-term.

CEO Transition Strategic Continuity

Q: "Dave, congratulations on the CEO role. Any strategic priorities you'd highlight that might differ from Gary's framework?"
— David Roman, Goldman Sachs

A: "I am grateful for the strong foundation he's created and honored to serve as Intuitive's next CEO. I'm excited to lead the company forward as we continue to advance the Quintuple Aim and deliver value for our stakeholders."
— David Rosa, CEO

Assessment: Continuity-first framing. Same Quintuple Aim + ecosystem investment priorities.

Tariff Impact and Geographic Flexibility

Q: "Tariff estimate revised down. Can you walk through the assumption set and any further mitigations?"
— Travis Steed, BofA

A: "We are currently estimating the impact of tariffs for the year to be approximately 100 basis points, plus or minus 20 basis points, lower than the estimate we provided on last quarter's earnings call, primarily reflecting the reduction of bilateral tariff rates relating to U.S.-China trade."
— Jamie Samath, CFO

Assessment: Tariff overhang easing meaningfully. Bulgaria + Mexico manufacturing footprint provide additional flexibility.

Force Feedback Clinical Evidence Progression

Q: "Force feedback is a key dV5 feature. How is clinical evidence building, and when do you expect to demonstrate impact at scale?"
— Anthony Petrone, Mizuho

A: "With respect to our digital ecosystem, customers continue to collect and publish data about force feedback and other aspects of da Vinci 5 through their use of case insights... While these results are early, we are encouraged to see results that are consistent with the core hypothesis of the value that forced feedback technology and case insights may bring to minimally invasive surgery."
— David Rosa, CEO

Assessment: Multi-quarter clinical evidence build. Force feedback differentiation will compound as evidence base grows.

What They're NOT Saying

1. Specific dV5 ASP trajectory through FY25/FY26
2. SP profitability vs. corporate average
3. China tender volume outlook specifics
4. Ion service margin profile
5. Force feedback as % of dV5 procedures
6. Trade-in net economics (system revenue + ARPU uplift)

Market Reaction

• Pre-print: Stock ~$525; YTD +5%; trailing 12M -2%; ~52x FY25 EPS
• After-hours: +4-5% on beat + raise + CEO transition smooth
• July 23 close: ~$544, +3.6% (+$19); volume 1.7x average

The reaction is appropriately constructive — revenue + EPS beats + FY guide raises + CEO transition clean. Multiple PT raises 5-10% post-print.

Street Perspective

Debate: dV5 Trade-In Cycle Sustainability

Bull view: Multi-year trade-in cycle structurally accretive — Xi base of 10K+ systems creates 4-5 year refresh runway.

Bear view: Trade-in pace may decelerate as Xi base saturates; ASP uplift modest at ~$50K per system.

Our take: Bull view stronger. Trade-in cycle has 3-5 years of strong tailwind ahead.

Debate: OUS Recovery Timing

Bull view: Macro pressures temporary; NHS 10-year plan + India/Korea momentum offset.

Bear view: Japan/China capital pressures structural; budget constraints multi-year.

Our take: Mixed. OUS multi-specialty growth +23% absorbs Japan/China weakness; structural over time.

Debate: ISRG Valuation at 52x FY25 EPS

Bull view: Premium justified by durable procedure growth + expanding ecosystem + multi-decade runway.

Bear view: Premium compressed in higher-rate environment; medical device peers de-rated.

Our take: Lean bull. 52x is at low end of ISRG range; +23% EPS growth justifies premium.

Model Update Needed

Valuation: Initiating PT range: Base $620 / Bull $700 / Bear $480. Base case 60x FY25 EPS $8.55 + multi-year compounder framework. At $544 post-print: base +14%; bull +29%; bear -12%. Up/down ratio ~2.5:1.

Thesis Scorecard

Action: Initiating at Outperform. Multi-quarter compounder thesis intact; dV5 trade-in cycle + OUS expansion + Ion utilization growth + SP scaling support sustained +mid-teens revenue + +20%+ EPS growth.